User:Mr. Ibrahem/Ofatumumab

Ofatumumab, sold under the brand name Arzerra among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. For CLL it is used for cases when fludarabine and alemtuzumab have failed. It is given by injection under the skin or into a vein.

Common side effects include upper respiratory tract infection, urinary tract infections, pain at the site of injection, headache, fever, and tiredness. Other side effects may include reactivation of hepatitis B and progressive multifocal leukoencephalopathy. Risk with breastfeeding is believed to be low. It is a monoclonal antibody that attaches to CD20 on B cells thus decreasing their activity.

Ofatumumab was approved for medical use in the United States in 2009. While it was approved for CLL in Europe in 2010, this approval was subsequently withdrawn. In 2021 Europe approved its use for MS. In the United Kingdom 20 mg of medication costs the NHS about £1,500. In the United States this amount costs about 7,500 USD.